Contents



Preface

Male reproductive health is an important area affecting men's overall health and well-being. Over the last few decades, there has been increasing concern regarding human male reproductive health. Estimates report that about one in three males suffers from andrological diseases. Infertility is a worldwide problem that affects approximately 15% of married couples. Half of these cases can be traced to male partners. Several risk factors have been identified that may have a negative impact on men's reproduction health, such as endocrine-disrupting chemicals. There is also evidence that endocrine-disrupting chemical exposure has multigenerational and transgenerational effects on reproductive disease. Infertile men are at an elevated risk of cancer development later in life, primarily genitourinary malignancies such as testicular and prostate cancer. This book will focus on male reproductive health, from the aspects of semen quality, male infertility, testicular cancer, and prostate

cancer, and their detection, diagnosis, treatment, and prevention.

mesenchymal stem cell therapy of male infertility.

ders in male patients treated for prostate carcinoma.

coeditors and coauthors for their efforts.

Section 1 discusses male infertility risk factors and therapy. The seven chapters of this section cover the potential early life causes of male infertility, effects of endocrine-disrupting chemicals in the male reproductive system and the decline of male fertility, evidence for the developmental programming of male reproductive maturation and function, mechanisms of Sertoli cell phagocytosis in spermatogenesis, polymorphism of xenobiotic detoxification genes and male infertility, and

Section 2 discusses testicular cancer and prostate cancer. The five chapters in this section cover testicular cancer and its early diagnosis, the role of MRI-TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer, pelvic health physical therapy and prostate cancer, combinatorial drug therapy with phytochemicals as adjuvants in prostate cancer management, and sexual and psychoemotional disor-

Many individuals have made this book a reality. Its completion would not have been possible without the efforts of numerous contributors. I would like to thank Ms. Dolores Kuzelj and Ms. Andrea Koric at IntechOpen for their strong support from inception to completion of this book. I would also like to acknowledge my

**Wei Wu**

China

Department of Toxicology, School of Public Health, Nanjing Medical University,
